{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T16:22:55Z","timestamp":1780417375225,"version":"3.54.1"},"reference-count":67,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Disease Clinics of North America"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.idc.2025.11.006","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T12:37:12Z","timestamp":1766061432000},"page":"149-164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Strategic Demonstration of the Clinical Utility of Nontraditional Antibacterials"],"prefix":"10.1016","volume":"40","author":[{"given":"Neha","family":"Prasad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumati","family":"Nambiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.idc.2025.11.006_bib1","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70495","article-title":"Burden of antimicrobial resistance in adult hospitalized patients with cancer: a multicenter analysis","volume":"13","author":"Gupta","year":"2024","journal-title":"Cancer Med"},{"issue":"5","key":"10.1016\/j.idc.2025.11.006_bib2","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S1470-2045(25)00128-7","article-title":"Incidence and prevalence of antimicrobial resistance in outpatients with cancer: a multicentre, retrospective, cohort study","volume":"26","author":"Gupta","year":"2025","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.idc.2025.11.006_bib3","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.3390\/antibiotics11101315","article-title":"Antimicrobial challenge in acute care surgery","volume":"11","author":"Schena","year":"2022","journal-title":"Antibiotics"},{"key":"10.1016\/j.idc.2025.11.006_bib4","series-title":"Combating antimicrobial resistance and protecting the miracle of modern medicine","article-title":"The national action plan for combating antibiotic-resistant bacteria","author":"Palmer","year":"2021"},{"key":"10.1016\/j.idc.2025.11.006_bib5","author":"Sullivan"},{"issue":"5","key":"10.1016\/j.idc.2025.11.006_bib6","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.mib.2003.08.003","article-title":"Why is big pharma getting out of antibacterial drug discovery?","volume":"6","author":"Projan","year":"2003","journal-title":"Curr Opin Microbiol"},{"key":"10.1016\/j.idc.2025.11.006_bib7","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.2217\/fmb-2019-0227","article-title":"Combating resistance while maintaining innovation: the future of antimicrobial stewardship","volume":"14","author":"Vickers","year":"2019","journal-title":"Future Microbiol"},{"issue":"5","key":"10.1016\/j.idc.2025.11.006_bib8","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s41579-019-0293-3","article-title":"Antibiotic development - economic, regulatory and societal challenges","volume":"18","author":"\u00c5rdal","year":"2020","journal-title":"Nat Rev Microbiol"},{"issue":"1","key":"10.1016\/j.idc.2025.11.006_bib9","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s44259-025-00123-1","article-title":"Current economic and regulatory challenges in developing antibiotics for Gram-negative bacteria","volume":"3","author":"Gargate","year":"2025","journal-title":"NPJ Antimicrob Resist"},{"issue":"7","key":"10.1016\/j.idc.2025.11.006_bib10","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41429-020-0300-y","article-title":"Industry incentives and antibiotic resistance: an introduction to the antibiotic susceptibility bonus","volume":"73","author":"Morel","year":"2020","journal-title":"J Antibiot (Tokyo)"},{"issue":"3","key":"10.1016\/j.idc.2025.11.006_bib11","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/cid\/cix320","article-title":"Challenges and opportunities of nontraditional approaches to treating bacterial infections","volume":"65","author":"Tse","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2025.11.006_bib12","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s44259-025-00087-2","article-title":"Emerging antimicrobial therapies for Gram-negative infections in human clinical use","volume":"3","author":"Hickson","year":"2025","journal-title":"NPJ Antimicrob Resist"},{"issue":"1","key":"10.1016\/j.idc.2025.11.006_bib13","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s44259-025-00096-1","article-title":"Antibiotics re-booted-time to kick back against drug resistance","volume":"3","author":"Blaskovich","year":"2025","journal-title":"NPJ Antimicrob Resist"},{"issue":"1","key":"10.1016\/j.idc.2025.11.006_bib14","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.chom.2019.06.004","article-title":"Non-traditional antibacterial therapeutic options and challenges","volume":"26","author":"Theuretzbacher","year":"2019","journal-title":"Cell Host Microbe"},{"issue":"1","key":"10.1016\/j.idc.2025.11.006_bib15","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1038\/s41467-019-11303-9","article-title":"Designing development programs for non-traditional antibacterial agents","volume":"10","author":"Rex","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.idc.2025.11.006_bib16","unstructured":"Website, Available at: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/development-non-traditional-therapies-bacterial-infections-08202018 (Accessed 12 August 2025)."},{"issue":"4","key":"10.1016\/j.idc.2025.11.006_bib17","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1086\/665010","article-title":"Policy statement on antimicrobial stewardship by the society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS)","volume":"33","year":"2012","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"9","key":"10.1016\/j.idc.2025.11.006_bib18","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/S1473-3099(17)30325-0","article-title":"Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis","volume":"17","author":"Baur","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2025.11.006_bib19","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1515\/dx-2024-0163","article-title":"CDC\u2019s Core elements to promote diagnostic excellence","volume":"12","author":"Morgan","year":"2025","journal-title":"Diagnosis (Berl)"},{"issue":"10","key":"10.1016\/j.idc.2025.11.006_bib20","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1093\/cid\/ciw118","article-title":"Implementing an antibiotic stewardship program: guidelines by the infectious diseases society of America and the society for healthcare epidemiology of America","volume":"62","author":"Barlam","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2025.11.006_bib21","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious diseases society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"21","key":"10.1016\/j.idc.2025.11.006_bib22","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1093\/ajhp\/zxad164","article-title":"ASHP\/SIDP joint statement on the pharmacist\u2019s role in antimicrobial stewardship","volume":"80","author":"Collins","year":"2023","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.idc.2025.11.006_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2023.1293633","article-title":"Antibiotic adjuvants: synergistic tool to combat multi-drug resistant pathogens","volume":"13","author":"Kumar","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"issue":"Suppl 2","key":"10.1016\/j.idc.2025.11.006_bib25","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1093\/cid\/ciw258","volume":"63","author":"Knirsch","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2025.11.006_bib26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/nyas.12441","article-title":"The evolution of the regulatory framework for antibacterial agents","volume":"1323","author":"Rex","year":"2014","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"10.1016\/j.idc.2025.11.006_bib27","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/cid\/cis503","article-title":"A paradigm shift in drug development for treatment of rare multidrug-resistant gram-negative pathogens","volume":"55","author":"Alemayehu","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2025.11.006_bib28","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41392-024-01760-0","article-title":"New clinical trial design in precision medicine: discovery, development and direction","volume":"9","author":"Duan","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"10.1016\/j.idc.2025.11.006_bib30","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/BF01709751","article-title":"The SOFA (Sepsis-related organ failure assessment) score to describe organ dysfunction\/failure. On behalf of the working group on sepsis-related problems of the european society of intensive care medicine","volume":"22","author":"Vincent","year":"1996","journal-title":"Intensive Care Med"},{"issue":"2","key":"10.1016\/j.idc.2025.11.006_bib31","article-title":"Critical parameters for the development of novel therapies for severe and resistant Infections-A case study on CAL02, a non-traditional broad-spectrum anti-virulence drug","volume":"9","author":"Azeredo da Silveira","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.idc.2025.11.006_bib32","unstructured":"Center for Drug Evaluation, Research, Multiple endpoints in clinical trials, 2024, U.S. Food and Drug Administration, Rockville (MD), Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/multiple-endpoints-clinical-trials (Accessed 12 August 2025)."},{"issue":"6","key":"10.1016\/j.idc.2025.11.006_bib33","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1093\/cid\/ciae043","article-title":"Exebacase in addition to standard-of-care antibiotics for Staphylococcus aureus bloodstream infections and right-sided infective endocarditis: a phase 3, superiority-design, placebo-controlled, randomized clinical trial (DISRUPT)","volume":"78","author":"Fowler","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2025.11.006_bib34","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/cid\/ciad576","article-title":"Moving beyond mortality: development and application of a desirability of outcome ranking (DOOR) endpoint for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia","volume":"78","author":"Howard-Anderson","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.idc.2025.11.006_bib35","doi-asserted-by":"crossref","first-page":"e1157","DOI":"10.1093\/cid\/ciac692","article-title":"Improving traditional registrational trial end points: development and application of a desirability of outcome ranking end point for complicated urinary tract infection clinical trials","volume":"76","author":"Howard-Anderson","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2025.11.006_bib37","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1186\/s13063-022-07047-5","article-title":"Safety and microbiological activity of phage therapy in persons with cystic fibrosis colonized with pseudomonas aeruginosa: study protocol for a phase 1b\/2, multicenter, randomized, double-blind, placebo-controlled trial","volume":"23","author":"Tamma","year":"2022","journal-title":"Trials"},{"key":"10.1016\/j.idc.2025.11.006_bib38","unstructured":"Center for Drug Evaluation, Research, Surrogate endpoint resources for drug and biologic development, 2024, U.S. Food and Drug Administration, Rockville (MD), Available at: https:\/\/www.fda.gov\/drugs\/development-resources\/surrogate-endpoint-resources-drug-and-biologic-development (Accessed 13 August 2025)."},{"issue":"25","key":"10.1016\/j.idc.2025.11.006_bib39","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1002\/sim.5403","article-title":"Biomarkers and surrogate endpoints in clinical trials","volume":"31","author":"Fleming","year":"2012","journal-title":"Stat Med"},{"issue":"8","key":"10.1016\/j.idc.2025.11.006_bib40","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.3390\/ph18081115","article-title":"Bacteriophage therapy: discovery, development, and FDA approval pathways","volume":"18","author":"Niazi","year":"2025","journal-title":"Pharmaceuticals"},{"issue":"9","key":"10.1016\/j.idc.2025.11.006_bib41","doi-asserted-by":"crossref","first-page":"ofaa389","DOI":"10.1093\/ofid\/ofaa389","article-title":"Lessons learned from the first 10 consecutive cases of intravenous bacteriophage therapy to treat multidrug-resistant bacterial infections at a single center in the United States","volume":"7","author":"Aslam","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"6","key":"10.1016\/j.idc.2025.11.006_bib42","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/s41564-024-01705-x","article-title":"Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study","volume":"9","author":"Pirnay","year":"2024","journal-title":"Nat Microbiol"},{"issue":"8","key":"10.1016\/j.idc.2025.11.006_bib43","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1093\/cid\/ciad335","article-title":"A retrospective, observational study of 12 cases of expanded-access customized phage therapy: production, characteristics, and clinical outcomes","volume":"77","author":"Green","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2025.11.006_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/v10020064","article-title":"The magistral phage","volume":"10","author":"Pirnay","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.idc.2025.11.006_bib45","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3389\/fphar.2019.00513","article-title":"Advantages and limitations of bacteriophages for the treatment of bacterial infections","volume":"10","author":"Principi","year":"2019","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.idc.2025.11.006_bib46","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s40560-024-00759-7","article-title":"Current status of bacteriophage therapy for severe bacterial infections","volume":"12","author":"Sawa","year":"2024","journal-title":"J Intensive Care"},{"issue":"8","key":"10.1016\/j.idc.2025.11.006_bib47","article-title":"Antimicrobial stewardship at transitions of care to outpatient settings: synopsis and strategies","volume":"11","author":"Liu","year":"2022","journal-title":"Antibiotics (Basel)"},{"issue":"3","key":"10.1016\/j.idc.2025.11.006_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0223822","article-title":"Barriers and facilitators to the uptake of an antimicrobial stewardship program in primary care: a qualitative study","volume":"15","author":"Jeffs","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.idc.2025.11.006_bib50","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ijid.2021.02.020","article-title":"Antibiotic stewardship in direct-to-consumer telemedicine consultations leads to high adherence to best practice guidelines and a low prescription rate","volume":"105","author":"Pedrotti","year":"2021","journal-title":"Int J Infect Dis"},{"issue":"12","key":"10.1016\/j.idc.2025.11.006_bib51","doi-asserted-by":"crossref","first-page":"e444","DOI":"10.1016\/S1473-3099(19)30284-1","article-title":"Non-inferiority versus superiority trial design for new antibiotics in an era of high antimicrobial resistance: the case for post-marketing, adaptive randomised controlled trials","volume":"19","author":"Lanini","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.idc.2025.11.006_bib52","unstructured":"Center for Drug Evaluation, Research, Limited population pathway for antibacterial and antifungal drugs \u2013 the LPAD pathway, 2025, U.S. Food and Drug Administration, Rockville (MD), Available at: https:\/\/www.fda.gov\/drugs\/development-resources\/limited-population-pathway-antibacterial-and-antifungal-drugs-lpad-pathway (Accessed 14 August 2025)."},{"issue":"4","key":"10.1016\/j.idc.2025.11.006_bib53","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1177\/00185787241230079","article-title":"When antimicrobial treatment and surgical prophylaxis collide: a stewardship opportunity","volume":"59","author":"Fiallo","year":"2024","journal-title":"Hosp Pharm"},{"issue":"5","key":"10.1016\/j.idc.2025.11.006_bib54","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1053\/j.ajkd.2020.08.011","article-title":"Opportunities to improve antibiotic prescribing in outpatient hemodialysis facilities: a report from the American society of Nephrology and centers for disease control and prevention antibiotic stewardship white paper writing group","volume":"77","author":"Apata","year":"2021","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/j.idc.2025.11.006_bib56","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41587-023-01759-y","article-title":"Engineered phage with antibacterial CRISPR-cas selectively reduce E. coli burden in mice","volume":"42","author":"Gencay","year":"2024","journal-title":"Nat Biotechnol"},{"issue":"5","key":"10.1016\/j.idc.2025.11.006_bib57","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/cid\/ciy171","article-title":"Bezlotoxumab for prevention of recurrent Clostridium difficile infection in patients at increased risk for recurrence","volume":"67","author":"Gerding","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2025.11.006_bib58","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1093\/cid\/ciaa1590","article-title":"Economic evaluations of new antibiotics: the high potential value of reducing healthcare transmission through decolonization","volume":"72","author":"Toth","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.idc.2025.11.006_bib59","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.ajic.2021.04.007","article-title":"The impact of infections on reimbursement in 92 US hospitals, 2015-2018","volume":"49","author":"Puzniak","year":"2021","journal-title":"Am J Infect Control"},{"key":"10.1016\/j.idc.2025.11.006_bib60","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13756-019-0471-0","article-title":"Value of hospital antimicrobial stewardship programs [ASPs]: a systematic review","volume":"8","author":"Nathwani","year":"2019","journal-title":"Antimicrob Resist Infect Control"},{"issue":"1","key":"10.1016\/j.idc.2025.11.006_bib61","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12916-020-1507-2","article-title":"Quantifying the economic cost of antibiotic resistance and the impact of related interventions: rapid methodological review, conceptual framework and recommendations for future studies","volume":"18","author":"Jit","year":"2020","journal-title":"BMC Med"},{"issue":"8","key":"10.1016\/j.idc.2025.11.006_bib62","doi-asserted-by":"crossref","first-page":"4840","DOI":"10.1128\/AAC.00825-16","article-title":"Systematic review and meta-analysis of clinical and economic outcomes from the implementation of hospital-based antimicrobial stewardship programs","volume":"60","author":"Karanika","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"10459","key":"10.1016\/j.idc.2025.11.006_bib63","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S0140-6736(24)01867-1","article-title":"Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050","volume":"404","year":"2024","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.idc.2025.11.006_bib64","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/j.jamda.2022.01.075","article-title":"Mortality, health care use, and costs of Clostridioides difficile infections in older adults","volume":"23","author":"Feuerstadt","year":"2022","journal-title":"J Am Med Dir Assoc"},{"issue":"11","key":"10.1016\/j.idc.2025.11.006_bib65","doi-asserted-by":"crossref","first-page":"ofac599","DOI":"10.1093\/ofid\/ofac599","article-title":"A baker\u2019s dozen of top antimicrobial stewardship intervention publications in non-hospital care settings in 2021","volume":"9","author":"Green","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2025.11.006_bib66","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s43856-024-00516-9","article-title":"Overcoming challenges in the economic evaluation of interventions to optimise antibiotic use","volume":"4","author":"Roope","year":"2024","journal-title":"Commun Med"},{"issue":"4","key":"10.1016\/j.idc.2025.11.006_bib67","first-page":"289","article-title":"Leveraging health systems to expand and enhance antibiotic stewardship in outpatient settings","volume":"50","author":"Rodzik","year":"2024","journal-title":"Jt Comm J Qual Patient Saf"},{"issue":"1","key":"10.1016\/j.idc.2025.11.006_bib68","doi-asserted-by":"crossref","DOI":"10.1017\/ash.2024.468","article-title":"Navigating performance measures for ambulatory antimicrobial stewardship: a review of HEDIS\u00ae and other metrics the steward should know","volume":"4","author":"Arena","year":"2024","journal-title":"Antimicrob Steward Healthc Epidemiol"},{"key":"10.1016\/j.idc.2025.11.006_bib69","article-title":"Studying new antibiotics for multidrug resistant infections: are today\u2019s patients paying for unproved future benefits?","volume":"360","author":"Powers","year":"2018","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.idc.2025.11.006_bib70","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/cid\/cix246","article-title":"Progress in the fight against multidrug-resistant bacteria 2005-2016: modern noninferiority trial designs enable antibiotic development in advance of epidemic bacterial resistance","volume":"65","author":"Rex","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.idc.2025.11.006_bib71","doi-asserted-by":"crossref","first-page":"ofaa083","DOI":"10.1093\/ofid\/ofaa083","article-title":"A broken antibiotic market: review of strategies to incentivize drug development","volume":"7","author":"Bhavnani","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.idc.2025.11.006_bib72","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01446-19","article-title":"One size fits all? Application of susceptible-dose-dependent breakpoints to pediatric patients and laboratory reporting","volume":"58","author":"Nielsen","year":"2019","journal-title":"J Clin Microbiol"}],"container-title":["Infectious Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089155202500100X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089155202500100X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T20:42:09Z","timestamp":1773780129000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S089155202500100X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S089155202500100X"],"URL":"https:\/\/doi.org\/10.1016\/j.idc.2025.11.006","relation":{},"ISSN":["0891-5520"],"issn-type":[{"value":"0891-5520","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Strategic Demonstration of the Clinical Utility of Nontraditional Antibacterials","name":"articletitle","label":"Article Title"},{"value":"Infectious Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idc.2025.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}